Business
Additional patent licence with Mount Sinai
Additional patent licence with Mount Sinai.
About this update from Verici Dx Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 1578L\n Verici Dx PLC\n 11 January 2021\n \n \n \n \n Verici Dx plc\n \n \n (\"Verici Dx\" or the \"Company\") \n \n \n \n \n Additional patent licence with Mount Sinai\n \n Worldwide exclusive licence to liquid biopsy IP for predicting risk of fibrosis and chronic damage rejection\n \n Strengthens patent portfolio covering the\n \n entire kidney transplant diagnostic pathway\n \n \n \n \n Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant,\n announces that it has expanded the scope of its licence agreement with the Icahn School of Medicine at Mount Sinai (\"Mount Sinai\") to include an additional patent filing related to the analysis of gene expression in a blood-based test (liquid biopsy) to predict risk of fibrosis (chronic kidney graft damage) and rejection of the graft. \n \n \n \n Interstitial fibrosis and tubular atrophy (IF/TA) is a\n significant complication in 50-65% of transplants at 12-24 month\n \n s1\n \n and a major cause of graft rejection in the first year after transplantation2. \n \n \n \n \n \n The development of a product that can predict risk of fibrosis and rejection using the Company's core technological approach would extend Verici Dx's portfolio across the full course of a patient's transplant journey and complement the \n Company's two flagship in vitro diagnostic assays, Clarava™ and Tuteva™. Clarava™ is a \n pre-transplant prognosis test for the risk of early acute rejection, and \n Tuteva™ is \n a post-transplant diagnostic focused upon acute cellular rejection. A further product using this technological approach and focused on risk of fibrosis would support the diagnosis of risk of longer-term graft failure as well. \n \n \n The development of a novel blood-based immune-phenotyping prognostic test for risk of fibrosis fits well with Verici Dx's current laboratory capabilities, instrumentation and expertise. Liquid biopsy also allows for easier deployment in clinical care given the limited population of transplant centres that undertake tissue allograft surveillance biopsies and the lower risk and costs associated with blood-based biopsies.\n \n The Company's multi-centre observational clinical study to validate the clinical performance of Clarava™ and Tuteva™ will also inclu...